Cyber Media (India) Regulatory Approval

Financial Results

Cyber Media (India) Q2 FY27 Results: Net Profit ₹1 Cr, Up 11.1% YoY

Cyber Media (India) Ltd reported revenue from operations of ₹46.8 Cr (+93.4% YoY) and net profit of ₹1 Cr (+11.1% YoY) for Q2 FY27.

Key figure

Net profit ₹1 Cr · +11.1% YoY

Acquisition

Cyber Media (India) Acquisition

NCLT Delhi allowed the First Motion for Cyber Media Research & Services merger into Cyber Media (India). Shareholder and creditor meetings are directed to approve the scheme.

Board Meeting Date

Cyber Media (India) Board Meeting Date

Cyber Media (India) Limited notified a board meeting on 26 Oct 2026 to consider Q1 FY27 unaudited results. No financial figures are disclosed in this advance intimation.

Other Announcement

Cyber Media (India) Other Announcement

The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026. This provides standard disclosures regarding shareholder ownership.

Legal & Regulatory

Cyber Media (India) Legal & Regulatory

Cyber Media (India) Limited received an assessment order from the Tamil Nadu Commercial Taxes Department demanding Rs. 0.97 Crore. The company intends to contest the tax demand legally.

Value

₹0.97 Cr

From

State Tax Officer, Commercial Taxes Department, Chennai

Legal & Regulatory

Cyber Media (India) Legal & Regulatory

Cyber Media (India) Limited received a tax demand order of ₹0.54 Crore from the Commercial Taxes Department. The company plans to legally contest the order.

Value

₹0.54 Cr

Regulatory ApprovalWanbury Ltd WANBURYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Regulatory ApprovalSandur Manganese & Iron Ores Ltd SANDUMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Regulatory ApprovalNeogen Chemicals Ltd NEOGENAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Regulatory ApprovalArihant Capital Markets Ltd ARIHANTCAPAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.